Join the Ulcerative Colitis group to help and get support from people like you.
Ulcerative Colitis News
Related terms: Colitis, Ulcerative, UC, Colitis Ulcerosa
Monthly News Roundup - March 2025
FDA Approves Tremfya for Adults Patients with Active Crohn’s Disease In March, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (guselkumab) for the t...
Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD
MONDAY, March 24, 2025 – Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting premature death,...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 – For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis, corticosteroid usage,...
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
WEDNESDAY, Feb 5, 2025 – Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study published in the March issue of...
Metrics From Wearable Devices Can Predict IBD Flares
FRIDAY, Jan. 24, 2025 – Physiological metrics from wearable devices can help identify inflammatory bowel disease (IBD) flares, according to a study published online Jan. 16 in Gastroenterology....
Intestinal Ultrasound Feasible for Detecting Pediatric Inflammatory Bowel Disease
FRIDAY, Jan. 3, 2025 – Intestinal ultrasound (IU) can be considered a screening tool for pediatric inflammatory bowel disease (IBD), according to a study published online Dec. 24 in the Journal of ...
Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
MONDAY, Dec. 23, 2024 – For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study...
FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...
Over 100,000 U.S. Youth Battle Inflammatory Bowel Disease
MONDAY, Dec.2, 2024 – Cases of inflammatory bowel disease (IBD) are rising at an alarming rate among young Americans, a new study reveals. "Prevalence rates [are] among the highest reported...
Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease
FRIDAY, Nov. 22, 2024 – An estimated 100,429 youth are living with pediatric inflammatory bowel disease (PIBD) in the United States, according to a research letter published online Nov. 20 in...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of Selarsdi (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
People With Inflammatory Bowel Disease Face Barriers to Health Care
MONDAY, Oct. 21, 2024 – Patients with inflammatory bowel disease (IBD) continue to experience barriers to health care access and treatment and financial struggles, according to a study published...
Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
FRIDAY, Oct. 18, 2024 – For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published online Oct. 15 in the...
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
Further information
Related condition support groups
Ulcerative Colitis - Active, Colitis
Related drug support groups
Humira, clonidine, hydrocortisone, Stelara, Entyvio, Remicade, Xeljanz, Skyrizi, dexamethasone, adalimumab, budesonide, ustekinumab